What Is Duchenne Muscular Dystrophy?

What is Duchenne muscular dystrophy? Duchenne muscular dystrophy, often shortened to DMD, is a genetic condition that causes progressive muscle weakness. It most often affects boys, although girls and women can be carriers and sometimes have symptoms.

The core problem in DMD

Muscles contract thousands of times a day. Dystrophin helps stabilize muscle cells during that stress. When dystrophin is missing or nearly missing, muscle fibers are more easily damaged and gradually replaced by fat and scar-like tissue. (MedlinePlus Genetics, DMD gene)

That is why Duchenne is not only a leg weakness condition. Over time it can affect skeletal muscles, the heart muscle, breathing muscles, and muscles involved in posture and daily movement. MDA describes Duchenne as a progressive disease with a typical childhood onset, although the exact course varies from person to person. (MDA, Duchenne Muscular Dystrophy)

How symptoms often appear

Early signs may include delayed walking, trouble running or climbing stairs, frequent falls, enlarged calves, and a movement pattern called Gowers’ sign, where a child uses the hands to push up from the floor. Some children also have speech, learning, or behavior differences.

A diagnosis is usually considered after a pattern of weakness, a high creatine kinase blood test, or a family history. Genetic testing is now central because it can confirm the mutation and may affect trial eligibility or treatment discussions. (Birnkrant et al., Lancet Neurology 2018 Part 1)

Why Duchenne progresses

DMD is progressive because the underlying muscle injury continues over time. Many boys lose independent walking in late childhood or adolescence, although corticosteroid treatment, cardiac care, respiratory care, rehabilitation, and newer therapies may change the timing for some patients. Duchenne UK emphasizes that there is no cure at present, but standards of care can improve quality of life and survival. (Duchenne UK, About Duchenne)

The heart and lungs matter because survival increasingly depends on anticipating complications rather than waiting for a crisis. The 2018 care considerations describe coordinated care across neuromuscular, rehabilitation, cardiac, pulmonary, endocrine, bone, nutrition, and psychosocial domains. (Birnkrant et al., Lancet Neurology 2018 Part 2)

What this means for families

For a family hearing the name for the first time, the most useful next step is usually not to memorize every therapy. It is to understand the diagnosis, the gene change, and which specialists should be involved. Families may want to ask the care team what the confirmed mutation is, which baseline heart and lung tests are needed, and how the child will be monitored over time.

It is also reasonable to ask how the diagnosis connects with school, mobility, vaccinations, nutrition, and emotional support. Duchenne changes many parts of daily life, but planning can reduce avoidable surprises.

What is still uncertain

The treatment landscape is changing, but no approved therapy reverses Duchenne for all patients. Some therapies apply only to specific mutations. Others are approved with evidence that regulators continue to follow. This is why DMD information should be checked against current medical guidance, not old internet summaries.

For more background, read the site’s guide to early signs of Duchenne and the DMD diagnosis pathway.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.